These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 16174047)
21. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. Coward RM; Simhan J; Carson CC BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450 [TBL] [Abstract][Full Text] [Related]
22. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day). Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579 [TBL] [Abstract][Full Text] [Related]
23. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. Andriole GL; Marberger M; Roehrborn CG J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723 [TBL] [Abstract][Full Text] [Related]
24. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Porter MP; Stanford JL; Lange PH Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738 [TBL] [Abstract][Full Text] [Related]
25. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer. Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455 [TBL] [Abstract][Full Text] [Related]
26. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study. Wada Y; Nakanishi J; Takahashi W; Kai N; Nakayama Y; Yamashita Y; Honda J; Ueda S BJU Int; 2006 Oct; 98(4):794-7. PubMed ID: 16978274 [TBL] [Abstract][Full Text] [Related]
27. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453 [TBL] [Abstract][Full Text] [Related]
28. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Schröder FH; Bangma CH; Roobol MJ Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712 [TBL] [Abstract][Full Text] [Related]
29. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. Kehinde EO; Mojiminiyi OA; Sheikh M; Al-Awadi KA; Daar AS; Al-Hunayan A; Anim JT; Al-Sumait AA BJU Int; 2005 Aug; 96(3):308-12. PubMed ID: 16042719 [TBL] [Abstract][Full Text] [Related]
30. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635 [TBL] [Abstract][Full Text] [Related]
31. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597 [TBL] [Abstract][Full Text] [Related]
32. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Xie W; Nakabayashi M; Regan MM; Oh WK Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608 [TBL] [Abstract][Full Text] [Related]
33. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States. Cheng I; Yu MC; Koh WP; Pike MC; Kolonel LN; Henderson BE; Stram DO Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1692-6. PubMed ID: 16030103 [TBL] [Abstract][Full Text] [Related]
34. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812 [TBL] [Abstract][Full Text] [Related]
35. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Schröder FH; Roobol MJ Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513 [TBL] [Abstract][Full Text] [Related]
36. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Ochiai A; Fritsche HA; Babaian RJ Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145 [TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan. Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926 [TBL] [Abstract][Full Text] [Related]
39. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Yang WJ; Lee DH; Chung BH; Cho JS; Choi YD; Kim SJ; Cho IR; Kim HS; Kim CI; Hong SJ; Urology; 2006 Feb; 67(2):333-6. PubMed ID: 16461083 [TBL] [Abstract][Full Text] [Related]
40. Changes in baseline PSA levels in Japanese men from 1988 to 2003. Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]